NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology
* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models.
* Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition.
* Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.
Reading : 15 min